Pancreatic Cancer Clinical Trial
Official title:
Endoscopic Ultrasound-guided Biliary Drainage for Malignant Biliary Obstruction After Failed ERCP: a Single Italian Center Experience
In this study the investigators retrospectively report outcomes of direct transluminal EUS-BD in a series of patients with malignant biliary obstruction after failed ERCP as the experience of a single Italian center
INTRODUCTION Endoscopic retrograde cholangiopancreatography (ERCP) with placement of biliary
stents is the treatment of choice for palliation of malignant obstructive jaundice and has a
success rate of 90% with low morbidity rate.1 In 5 to 10% of cases, even in expert hands,
stents' placement failed for several reasons as altered anatomy due to surgical intervention,
gastric outlet obstruction, ampullary tumors invasion, high grade biliary strictures and all
other causes of failed biliary cannulation.
In these unfortunately cases alternative methods have been developed. Percutaneous
transhepatic biliary drainage (PTDB) is a efficacy technique but is associated with an
adverse events rate of 30% and a negative impact on the quality of life of patients due to
the external drainage;4 furthermore surgical biliodigestive anastomosis is burdened by a
morbidity and mortality of 30% and 10% respectively.
An effective alternative to PTDB, introduced for the first time in 1996, is endoscopic
ultrasonography-guided biliary drainage (EUS-BD). EUS-BD can be performed by four different
routes: EUS-guided hepaticogastrostomy, choledochoduodenostomy, rendezvous and anterograde
transpapillary drainage.
Among these, rendezvous technique seems to be the safest of all EUS-guided procedure at the
expense of a not excellent success rate (from 44% to 80%) and with the limit of the need of a
accessible papilla by endoscopy.8 These limitations are overcome by direct transluminal
EUS-guided approach as hepaticogastrostomy and choledochoduodenostomy that also ensure a
1-stage procedure.
In this study the investigators retrospectively report outcomes of direct transluminal EUS-BD
in a series of patients with malignant biliary obstruction after failed ERCP as the
experience of a single Italian center.
Definitions:
Technical success was defined as the correct placement of the metal or plastic stent across
the stomach or duodenum to the chosen biliary branch, with radiologically and endoscopically
confirmed.
Early clinical success was defined as a drop of bilirubin hematic level by 50 % after 2 week
from EUS-BD, while late clinical success was considered as the reaching of hematic bilirubin
level compatible with a possible chemotherapy treatment at 3-4 weeks after the endoscopic
performance.
Procedure-related adverse events were recorded and graded as mild if they resolved
spontaneously, moderate if they required a specific intervention without the need for an
extension of hospitalization and severe in case of death or if they required a specific
intervention (surgical or not) with consequent prolongation of hospitalization.
Stent patency duration was defined as the time between stent placement and its occlusion
Re-stenting was defined as the necessary to second EUS-guided stent placement in patients who
didn't achieve early clinical success or in the case of jaundice recurrence from the first
treatment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|